The Pershing Square chief is back on for dinner at Marea on Dec. 18, while Valeant Pharmaceuticals will have to settle for about $400 million of his winnings and maybe some other sacrificial lamb-drug company that Ackman might care to throw its way.
"We congratulate Actavis and Allergan on their announced transaction. As a result of the deal, we are withdrawing our special meeting request," Ackman said in an e-mailed statement.
Ackman supports Allergan’s $66 billion sale to Actavis [Reuters]
Allergan Escapes Valeant’s Pursuit, Agreeing to Be Bought by Actavis [DealBook]
Winners and Losers From the $100 Billion M&A Day [WSJ MoneyBeat blog]